Nebula Research & Development LLC Takes $354,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Nebula Research & Development LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 14,027 shares of the biopharmaceutical company's stock, valued at approximately $354,000.

A number of other institutional investors also recently added to or reduced their stakes in CLDX. EverSource Wealth Advisors LLC lifted its position in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares during the period. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the 4th quarter valued at $81,000. KBC Group NV increased its stake in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aristides Capital LLC purchased a new position in Celldex Therapeutics in the 4th quarter valued at $202,000.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price for the company. Morgan Stanley started coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target on the stock. The Goldman Sachs Group dropped their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Friday, February 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.30.

Celldex Therapeutics Trading Down 0.2 %

NASDAQ:CLDX traded down $0.05 on Friday, hitting $20.66. 598,699 shares of the stock were exchanged, compared to its average volume of 884,988. The stock has a market cap of $1.37 billion, a PE ratio of -8.04 and a beta of 1.59. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock has a fifty day moving average of $19.09 and a 200-day moving average of $23.17.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.